Research Article
Clinically Applicable Diagnostics Assay Development for Lung Cancer Biomarker, SAA
Hye-Jin Sung1, Sang-Su Na1,3, Keyung-Jo Seul2, Hyo-Sung Jeon4, Jae Yong Park4,5 and Je-Yoel Cho1*
1Department of Biochemistry, BK21 PLUS Program for Creative Veterinary Science Research and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, South Korea
2ProtAnBio, Seoul, Daegu University, South Korea
3Department of Physical Therapy, College of Rehabilitation, Daegu University, Daegu, South Korea
4Departments of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
5Lung Cancer Center, Kyungpook National University Medical Center, Daegu, Republic of Korea
- *Corresponding Author:
- Je-Yoel Cho, PhD
Associate Professor, Department of Biochemistry
College of Veterinary Medicine, Seoul National University
Daehakdong, Gwanak-gu, Seoul, Korea 151-742
Tel: +82-02-880-1268
Fax: +82-02-886-1268
E-mail: [email protected]
Received Date: August 04, 2014; Accepted Date: September 03, 2014; Published Date: September 08, 2014
Citation: Sung HJ, Na SS, Seul KJ, Jeon HS, Park JY, et al. (2014) Clinically Applicable Diagnostics Assay Development for Lung Cancer Biomarker, SAA. J Proteomics Bioinform 7:303-309. doi: 10.4172/jpb.1000333
Copyright: © 2014 Sung HJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
| Peer-reviewed Full Article 
Abstract
Background: Serum Amyloid A (SAA) is an acute phase protein and has been reported as a lung cancer biomarker. Many cancer protein biomarkers have been reported but few are currently in clinical application. This is due to the obstacles in the process from biomarker discovery to biomarker application: validation in large scale clinical samples and paired antibody production for the development of immunoassay-based diagnostics.
Methods: To develop immunoassay-based diagnostics of SAA, we produced anti-SAA monoclonal antibodies after bacterial production of pure SAA whole protein immunogen. Using two SAA specific monoclonal antibody clones, we developed two types of diagnostics; ELISA and rapid tester diagnostics. Hundreds of clinical samples were tested using the immunoassay diagnostics developed.
Results: The diagnostic or differential diagnostic ability of lung cancer from healthy control or respiratory diseases was tested by developed ELISA or rapid tester kits using hundreds of clinical samples. Developed ELISA kit turned out to measure SAA precisely and clinical sample tests showed that, as previously reported, SAA level is significantly higher in lung cancer groups compared with healthy controls or lung diseases (p<0.05). The test results of secondly developed rapid tester kit also showed lung cancer specific positive signals (p<0.05).
Conclusion: Both types of immunoassays showed significant diagnostic capability of SAA. This study demonstrated the potential of developed immunoassays for the clinical lung cancer diagnostics.
